Scancell Hldgs Plc (SCLP) - Total Liabilities
Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has total liabilities worth GBX23.75 Million GBX (≈ $2.89K USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SCLP cash flow conversion to assess how effectively this company generates cash.
Scancell Hldgs Plc - Total Liabilities Trend (2005–2025)
This chart illustrates how Scancell Hldgs Plc's total liabilities have evolved over time, based on quarterly financial data. See SCLP total equity for net asset value and shareholders' equity analysis.
Scancell Hldgs Plc Competitors by Total Liabilities
The table below lists competitors of Scancell Hldgs Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
C3is Inc.
NASDAQ:CISS
|
USA | $11.27 Million |
|
Hedera Group publ AB
ST:HEGR
|
Sweden | Skr125.90 Million |
|
Globavend Holdings Limited Ordinary Shares
NASDAQ:GVH
|
USA | $2.79 Million |
|
Binakarya Jaya Abadi Tbk PT
JK:BIKA
|
Indonesia | Rp3.41 Trillion |
|
Bastion Minerals Ltd
AU:BMO
|
Australia | AU$1.90 Million |
|
Cathedra Bitcoin Inc
V:CBIT
|
Canada | CA$10.46 Million |
|
Baiya International Group Inc. Ordinary Shares
NASDAQ:BIYA
|
USA | $4.40 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Scancell Hldgs Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SCLP stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scancell Hldgs Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scancell Hldgs Plc (2005–2025)
The table below shows the annual total liabilities of Scancell Hldgs Plc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | GBX26.93 Million ≈ $3.28K |
-0.58% |
| 2024-04-30 | GBX27.08 Million ≈ $3.29K |
-25.81% |
| 2023-04-30 | GBX36.50 Million ≈ $4.44K |
+23.43% |
| 2022-04-30 | GBX29.57 Million ≈ $3.60K |
+2427.61% |
| 2021-04-30 | GBX1.17 Million ≈ $142.36 |
-2.94% |
| 2020-04-30 | GBX1.21 Million ≈ $146.66 |
0.00% |
| 2019-04-30 | GBX1.21 Million ≈ $146.66 |
+73.17% |
| 2018-04-30 | GBX696.09K ≈ $84.69 |
+30.87% |
| 2017-04-30 | GBX531.88K ≈ $64.71 |
-7.60% |
| 2016-04-30 | GBX575.65K ≈ $70.04 |
-4.68% |
| 2015-04-30 | GBX603.91K ≈ $73.48 |
+12.34% |
| 2014-04-30 | GBX537.59K ≈ $65.41 |
+70.60% |
| 2013-04-30 | GBX315.11K ≈ $38.34 |
+10.81% |
| 2012-04-30 | GBX284.38K ≈ $34.60 |
+133.10% |
| 2011-04-30 | GBX122.00K ≈ $14.84 |
-73.01% |
| 2010-04-30 | GBX452.00K ≈ $55.00 |
+170.66% |
| 2009-04-30 | GBX167.00K ≈ $20.32 |
+89.02% |
| 2008-04-30 | GBX88.35K ≈ $10.75 |
-57.15% |
| 2007-04-30 | GBX206.21K ≈ $25.09 |
+415.52% |
| 2006-04-30 | GBX40.00K ≈ $4.87 |
-31.03% |
| 2005-08-31 | GBX58.00K ≈ $7.06 |
-- |
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more